Eli Lilly breaks ground on $6.5B Houston API and advanced therapeutics site

Key highlights
  • $6.5 billion Houston facility will manufacture APIs including Foundayo, other small molecules, and advanced therapeutics such as oligonucleotides.
  • The site is expected to create more than 600 permanent high-wage jobs and about 4,000 construction jobs.
  • Lilly is providing $12.5 million to San Jacinto College for training pathways and $2.5 million in scholarships to the college foundation.
  • The project is one of ten U.S. sites announced since 2020 and the company’s fifth API location; Foundayo is under review in 40+ countries with a full global rollout targeted for 2027.
Related project For subscribers
Milestones, plant data, involved companies (owners, investors, licensors, contractors) and news — kept up to date.
Lilly Houston API plant · United States
Under Construction
2025-09-23
2026-09-21
—
Operational / Completed · expected date for subscribers

Project overview

Eli Lilly has broken ground on a $6.5 billion manufacturing site in Houston to produce active pharmaceutical ingredients (API) and advanced therapeutics. The investment is part of a broader $50 billion effort to reshore medicine production and is the company’s fifth U.S. API location announced since 2020.

Products and capacity

The Houston plant will manufacture Foundayo (orforglipron), Lilly’s first synthetic oral GLP‑1 small molecule, alongside other small‑molecule medicines and advanced modalities such as oligonucleotides. Foundayo is under regulatory review in more than 40 countries, with a full global rollout targeted for 2027.

Workforce and training

The site is expected to create more than 600 high‑wage jobs and approximately 4,000 construction jobs. Lilly is investing $12.5 million to partner with San Jacinto College on training pathways for technicians, operators and maintenance staff, and is donating $2.5 million to the college foundation for scholarships.

Operations and network

The Houston facility will use machine learning, AI, digitally integrated systems and advanced data analytics to drive right‑first‑time execution and digital automation across operations. It joins a ten‑site U.S. expansion that includes API sites in Richmond, VA; Huntsville, AL; Houston, TX; and two locations in Lebanon, IN, plus facilities for injectables, devices and genetic medicines.

Source: Lilly

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

9 November 2026
Lilly's Foundayo (orforglipron) cuts OSA severity and hypoxic burden in Phase 3 ATTAIN-OSA

Phase 3 ATTAIN-OSA showed up to 44% AHI reduction, up to 55.9% lower hypoxic burden, ~11–11.5% weight loss, and improvements in blood pressure and inflammation; FDA submission planned by end of 2026.

6 November 2026
Lilly and Hims & Hers broaden access to Lilly’s Zepbound and Foundayo

Eligible patients can obtain Zepbound (tirzepatide) and Foundayo (orforglipron) via Hims & Hers telehealth with self-pay prices from $149/month for Foundayo and $299/month for Zepbound.

28 October 2026
Lilly’s retatrutide outperforms Ozempic 2 mg in A1C and weight loss in Phase 3 head‑to‑head

At 80 weeks retatrutide lowered A1C by 2.2% and reduced weight ~20% (44–47 lbs) versus Ozempic 2 mg’s 1.8% A1C reduction and 9.4% (~21 lbs) weight loss.

30 September 2026
Lilly's EloraTZP (eloralintide + tirzepatide) outperforms tirzepatide 15 mg in Phase 2b obesity and T2D trial

Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.

30 September 2026
Lilly’s Foundayo shows cardiovascular safety and durable A1C and weight benefits in ACHIEVE‑4

Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.